Analysts expect Boston Scientific to report Q1 2026 revenue of $5.18 billion and adjusted EPS of $0.79, while the stock currently trades near $60.84 against a consensus price target of $93.91.
The primary focus for investors remains the momentum in the Cardiovascular segment, specifically the market adoption of the FARAPULSE Pulsed Field Ablation (PFA) system.
While the company has seen robust top-line growth, recent sentiment has been tempered by a downward revision to full-year 2026 guidance due to emerging headwinds in some regional markets. Investors are also monitoring the performance of the WATCHMAN franchise following recent clinical trial updates and competitive pressure in the electrophysiology space.